Yumanity Therapeutics Statistics Share Statistics Yumanity Therapeutics has 8.32M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 8.32M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 50.82M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 65.07K, so 0% of the outstanding
shares have been sold short.
Short Interest 65.07K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.44 and the forward
PE ratio is null.
Yumanity Therapeutics's PEG ratio is
-0.04.
PE Ratio -0.44 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio -0.62 P/FCF Ratio -0.65 PEG Ratio -0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Yumanity Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.08,
with a Debt / Equity ratio of -0.05.
Current Ratio 0.08 Quick Ratio 0.08 Debt / Equity -0.05 Debt / EBITDA -0.05 Debt / FCF -0.05 Interest Coverage -98.06
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-428.3K Employee Count 40 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0, so Yumanity Therapeutics's
price volatility has been lower than the market average.
Beta 0 52-Week Price Change n/a 50-Day Moving Average 1.76 200-Day Moving Average 1.57 Relative Strength Index (RSI) 51.71 Average Volume (20 Days) 132,360
Income Statement
Revenue n/a Gross Profit n/a Operating Income -13.53M Net Income -17.13M EBITDA -13.53M EBIT n/a Earnings Per Share (EPS) -1.42
Full Income Statement Balance Sheet The company has 634K in cash and 629K in
debt, giving a net cash position of 5K.
Cash & Cash Equivalents 634K Total Debt 629K Net Cash 5K Retained Earnings -182.92M Total Assets 17.5M Working Capital 3.65M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -11.57M
and capital expenditures 0, giving a free cash flow of -11.57M.
Operating Cash Flow -11.57M Capital Expenditures n/a Free Cash Flow -11.57M FCF Per Share -0.96
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields YMTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for YMTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 19, 2022. It was a
backward
split with a ratio of 1:7.
Last Split Date Dec 19, 2022 Split Type backward Split Ratio 1:7
Scores Altman Z-Score -21.89 Piotroski F-Score 3
